Nerofe™

First Compound combining Immune and anti-Angiogenesis treatment of cancer.

Immune System Key

Nerofe™ , the flagship compound of the company, is a 14 amino acid modified form of a novel human hormone-peptide, which was found to be a native ligand of the ST2 receptor and plays a pivotal role in immune system response.

www.immuneSK.com

Nerofe™ - Features

- Nerofe™ is cytotoxic for cancer and inflamed cells, but does not affect healthy cells.
- Nerofe™ activates immune system response.
- Nerofe™ inhibits angiogenesis.





Nerofe™ - Effects

ISK Ltd. has finished a dose escalation Phase I clinical trial (3+3) in patients suffering from advanced/metastatic tumors. We found that Nerofe™ has:

- **An excellent safety profile.** No hematological or other life threatening adverse events were observed.
- **Progression Free Survival (PFS)** was observed in 6 out of 15 patients (during 3.5, 4, 6 and 12 month).
- **A strong multiple-factor anti-angiogenesis effect** was observed in all patients of two cohorts, which show orders of magnitude decrease of the following plasma angiogenesis factors: VEGF-A, VEGF-D, PDGF-AA, PDGF-BB, aFGF, bFGF and Angiopoietin-1.
- **A strong anti-proliferative effect**: in 3 patients high levels of EGF were decreased to the normal levels.
- **An immune-modulatory effect and selective biomarker** to pre-assess treatment efficacy: all patients with biopsies positively stained to ST2 receptor have demonstrated an increase in TNF-alpha, IL-2, IL-21, IL-12p70 and GM-CSF plasma levels during the treatment. Their PFS was longer than 6 months.
- In one patient diagnosed with spinal cord neoplasm the tumor was transformed to neurofibroma: before treatment more than 30% of cells in tumor were dividing, while after treatment less than 10% dividing (ki67 positive) cells were observed. In post treatment biopsy considerable bleeding was present due to damage to blood vessels.





- **Tumor volume shrinkage** in a patient with Pancreatic cancer



ISK Senior staff

Dr. Yoram Devary, PhD, Founder, Chairman and CTO

Dr. Devary is an expert in the molecular mechanisms of cell's transformation.
He holds a Ph.D. degree in Biotechnology from the University of California, San Diego (UCSD).
Dr Devary has published several papers in distinguished journals such as Cell and Science .

Prof. Uziel Sandler, PhD, Founder, Vice-Chairman and CEO

Professor Uziel Sandler is one of the founders of "Fuzzy Dynamics", which describes evolution of complex systems with uncertainty dynamics laws. He is also an expert in DNA and Molecular Dynamics and Evolutionary Computations. He has published more than 80 academic articles in prestigious scientific journals and three books including "Neural Cell Behavior and Fuzzy Logic", Springer, NY, 2008

Company Profile

Immune System Key Ltd. was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary. It is a privately held company, engaged in discovery and development of innovative treatments to malignant and autoimmune diseases with strong unmet needs. Its assets are based on novel human secreted peptides, which were discovered by the founders. ISK's lead compound is Nerofe™. Nerofe™ was granted by the FDA with orphan drug status for AML treatment. The company is now in preparation for phase IIa. The company holds 3 worldwide patents on the molecule and its applications.